Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

被引：1
|
作者：
Fakih, Marwan
Cleary, James M.
Hong, Yong Sang
Kim, Tae-You
Safyan, Rachael A.
Allen, Simon
Bailey, Lorna
Cha, Edward
Lenain, Christelle
Lu, Danny
Schulze, Jochen
Shemesh, Colby S.
Zimmermann, Stefan
机构：
[1] City Hope Comprehens Med Ctr, Duarte, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Columbia Univ, Irving Med Ctr, New York, NY USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[10] Univ Hosp Lausanne, Immunooncol Serv, Dept Oncol, Lausanne, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3559
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
    Andre, T.
    Saunders, M. P.
    Kanehisa, A.
    Gandossi, E.
    Fougeray, R.
    Causse-Amellal, N.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 250 - 250
  • [32] Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV plus FOLFIRI versus BEV plus XELIRI (FNCLCC ACCORD 13/0503 study)
    Ducreux, M.
    Adenis, A.
    Mendiboure, J.
    Francois, E.
    Boucher, E.
    Chauffert, B.
    Ychou, M.
    Pierga, J.
    Montoto-Grillot, C.
    Conroy, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Regorafenib plus nivolumab in patients with mismatch repair- proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
    Fakih, Marwan
    Raghav, Kanwal Pratap Singh
    Chang, David Z.
    Larson, Tim
    Cohn, Allen L.
    Huyck, Timothy K.
    Cosgrove, David
    Fiorillo, Joseph A.
    Tam, Rachel
    D'Adamo, David
    Sharma, Neelesh
    Brennan, Barbara J.
    Wang, Ying A.
    Coppieters, Sabine
    Zebger-Gong, Hong
    Weispfenning, Anke
    Seidel, Henrik
    Ploeger, Bart A.
    Mueller, Udo
    de Oliveira, Carolina Soares Viana
    Paulson, Andrew Scott
    ECLINICALMEDICINE, 2023, 58
  • [34] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
    Beslija, S.
    Koza, I.
    Ocvirk, J.
    Ciuleanu, T.
    Kurteva, G.
    Papamichael, D.
    Vrbanec, D.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
  • [35] A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).
    Sadahiro, Sotaro
    Suzuki, Toshiyuki
    Tanaka, Akira
    Okada, Kazutake
    Saito, Gota
    Miyakita, Hiroshi
    Ogimi, Takashi
    Chan, Lin Fung
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [36] Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
    Antoniotti, Carlotta
    Rossini, Daniele
    Pietrantonio, Filippo
    Catteau, Aurelie
    Salvatore, Lisa
    Lonardi, Sara
    Boquet, Isabelle
    Tamberi, Stefano
    Marmorino, Federica
    Moretto, Roberto
    Ambrosini, Margherita
    Tamburini, Emiliano
    Tortora, Giampaolo
    Passardi, Alessandro
    Bergamo, Francesca
    Kassambara, Alboukadel
    Sbarrato, Thomas
    Morano, Federica
    Ritorto, Giuliana
    Borelli, Beatrice
    Boccaccino, Alessandra
    Conca, Veronica
    Giordano, Mirella
    Ugolini, Clara
    Fieschi, Jacques
    Papadopulos, Alexia
    Massoue, Clementine
    Aprile, Giuseppe
    Antonuzzo, Lorenzo
    Gelsomino, Fabio
    Martinelli, Erika
    Pella, Nicoletta
    Masi, Gianluca
    Fontanini, Gabriella
    Boni, Luca
    Galon, Jerome
    Cremolini, Chiara
    LANCET ONCOLOGY, 2022, 23 (07): : 876 - 887
  • [37] Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
    Felip, E.
    Lim, F. L.
    Johnson, M.
    O'Brien, M.
    Barlesi, F.
    Mazieres, J.
    Solomon, B.
    Moreno, V.
    Boni, V.
    Swalduz, A.
    Goldberg, S.
    Keam, B.
    Allen, S.
    Helms, H-J.
    Shemesh, C.
    Pintoffl, J.
    Al-Sakaff, N.
    Bailey, L.
    Sayyed, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S850 - S850
  • [38] Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study
    Pietrantonio, F.
    Ho, G. F.
    Su, Y-L.
    Chen, E. X.
    Yuan, Y.
    Voon, P-J.
    Liang, X.
    Jonker, D.
    Longo Munoz, F.
    Hecht, J. R.
    Chandana, S.
    Arnold, D.
    Bhattacharya, R.
    Curtin, J. C.
    Maul, S.
    Iwasawa, R.
    Chowdhury, S.
    Schnepp, R. W.
    Baig, M.
    Hong, Y. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S434 - S434
  • [39] FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
    Antoniotti, Carlotta
    Rossini, Daniele
    Pietrantonio, Filippo
    Salvatore, Lisa
    Marmorino, Federica
    Ambrosini, Margherita
    Lonardi, Sara
    Bensi, Maria
    Moretto, Roberto
    Tamberi, Stefano
    Toma, Ilaria
    Passardi, Alessandro
    De Grandis, Maria Caterina
    Conca, Veronica
    Palermo, Federica
    Cappetta, Alessandro
    Catteau, Aurelie
    Boni, Luca
    Galon, Jerome
    Cremolini, Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).
    Fakih, Marwan
    Segal, Neil Howard
    Schlechter, Benjamin L.
    Andre, Thierry
    Pietrantonio, Filippo
    Johnson, Benny
    Vasilyev, Alexander
    Krishnamurthi, Smitha S.
    Siena, Salvatore
    Messersmith, Wells A.
    Silva, Virgilio
    Paulson, Andrew Scott
    Elez, Elena
    Eng, Cathy
    Tejpar, Sabine
    Ducreux, Michel Pierre
    Wu, Wei
    Grossman, Joseph Elan
    Van Cutsem, Eric
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 23 - 23
12345